ReP USP - Resultado da busca

Artigo de periodico
Brazil’s unified health system: the first 30 years and prospects for the future (2019)
Castro, Marcia C; Massuda, Adriano; Almeida, Gisele; Menezes-Filho, Naércio Aquino ; Andrade, Mônica Viegas; Noronha, Kenya Valéria Micaela de Souza; Rocha, Rudi; Macinko, James; Hone, Thomas; Tasca, Renato; Giovanella, Lígia; Malik, Ana Maria; Werneck, Heitor; Fachini, Luiz Augusto; Atun, Rifat A
Fonte: Lancet. Unidade: FEA
Assuntos: SAÚDE PÚBLICA, POLÍTICA DE SAÚDE, SISTEMA DE SAÚDE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CASTRO, Marcia C et al. Brazil’s unified health system: the first 30 years and prospects for the future. Lancet, v. 394, n. 10195, p. 345-356, 2019Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(19)31243-7. Acesso em: 31 ago. 2024.
APA
Castro, M. C., Massuda, A., Almeida, G., Menezes-Filho, N. A., Andrade, M. V., Noronha, K. V. M. de S., et al. (2019). Brazil’s unified health system: the first 30 years and prospects for the future. Lancet, 394( 10195), 345-356. doi:10.1016/S0140-6736(19)31243-7
NLM
Castro MC, Massuda A, Almeida G, Menezes-Filho NA, Andrade MV, Noronha KVM de S, Rocha R, Macinko J, Hone T, Tasca R, Giovanella L, Malik AM, Werneck H, Fachini LA, Atun RA. Brazil’s unified health system: the first 30 years and prospects for the future [Internet]. Lancet. 2019 ; 394( 10195): 345-356.[citado 2024 ago. 31 ] Available from: https://doi.org/10.1016/S0140-6736(19)31243-7
Vancouver
Castro MC, Massuda A, Almeida G, Menezes-Filho NA, Andrade MV, Noronha KVM de S, Rocha R, Macinko J, Hone T, Tasca R, Giovanella L, Malik AM, Werneck H, Fachini LA, Atun RA. Brazil’s unified health system: the first 30 years and prospects for the future [Internet]. Lancet. 2019 ; 394( 10195): 345-356.[citado 2024 ago. 31 ] Available from: https://doi.org/10.1016/S0140-6736(19)31243-7
Artigo de periodico-carta/editorial
Alcohol consumption and vascular disease: other points to consider (2019)
Chen, Che-Hong; Ferreira, Julio Cesar Batista ; Mochly-Rosen, Daria; Gross, Eric R
Fonte: Lancet. Unidade: ICB
Assuntos: ANATOMIA, DOENÇAS VASCULARES, ACIDENTE VASCULAR CEREBRAL, ALCOOLISMO, TABAGISMO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CHEN, Che-Hong et al. Alcohol consumption and vascular disease: other points to consider. Lancet. London: Instituto de Ciências Biomédicas, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/S0140-6736(19)31880-X. Acesso em: 31 ago. 2024. , 2019
APA
Chen, C. -H., Ferreira, J. C. B., Mochly-Rosen, D., & Gross, E. R. (2019). Alcohol consumption and vascular disease: other points to consider. Lancet. London: Instituto de Ciências Biomédicas, Universidade de São Paulo. doi:10.1016/S0140-6736(19)31880-X
NLM
Chen C-H, Ferreira JCB, Mochly-Rosen D, Gross ER. Alcohol consumption and vascular disease: other points to consider [Internet]. Lancet. 2019 ; 394( 10209): 1617-1618.[citado 2024 ago. 31 ] Available from: https://doi.org/10.1016/S0140-6736(19)31880-X
Vancouver
Chen C-H, Ferreira JCB, Mochly-Rosen D, Gross ER. Alcohol consumption and vascular disease: other points to consider [Internet]. Lancet. 2019 ; 394( 10209): 1617-1618.[citado 2024 ago. 31 ] Available from: https://doi.org/10.1016/S0140-6736(19)31880-X
Artigo de periodico
Health effects of dietary risks in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 (2019)
Benseñor, Isabela M; Goulart, Alessandra Carvalho; Lotufo, Paulo Andrade; Agrawal, Sutapa; Cahill, Leah E
Fonte: Lancet. Unidades: FM, HU
Assuntos: DIRETRIZES PARA A PRÁTICA CLÍNICA, ANÁLISE GLOBAL, EPIDEMIOLOGIA ANALÍTICA, FATORES DE RISCO, DIETÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BENSEÑOR, Isabela M et al. Health effects of dietary risks in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, v. 393, n. 10184, p. 1958-1972, 2019Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(19)30041-8. Acesso em: 31 ago. 2024.
APA
Benseñor, I. M., Goulart, A. C., Lotufo, P. A., Agrawal, S., & Cahill, L. E. (2019). Health effects of dietary risks in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 393( 10184), 1958-1972. doi:10.1016/S0140-6736(19)30041-8
NLM
Benseñor IM, Goulart AC, Lotufo PA, Agrawal S, Cahill LE. Health effects of dietary risks in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 [Internet]. Lancet. 2019 ; 393( 10184): 1958-1972.[citado 2024 ago. 31 ] Available from: https://doi.org/10.1016/S0140-6736(19)30041-8
Vancouver
Benseñor IM, Goulart AC, Lotufo PA, Agrawal S, Cahill LE. Health effects of dietary risks in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 [Internet]. Lancet. 2019 ; 393( 10184): 1958-1972.[citado 2024 ago. 31 ] Available from: https://doi.org/10.1016/S0140-6736(19)30041-8
Artigo de periodico
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study (2019)
Burtness, Barbara; Harrington, Kevin J; Greil, Richard; Soulieres, Denis; Tahara, Makoto; Castro Junior, Gilberto de Castro ; Psyrri, Amanda; Baste, Neus; Neupane, Prakash; Bratland, Ase
Fonte: Lancet. Unidade: FM
Assuntos: CARCINOMA DE CÉLULAS ESCAMOSAS, NEOPLASIAS DE CABEÇA E PESCOÇO, ANTICORPOS MONOCLONAIS, ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BURTNESS, Barbara et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet, v. 394, n. 10212, p. 1915-1928, 2019Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(19)32591-7. Acesso em: 31 ago. 2024.
APA
Burtness, B., Harrington, K. J., Greil, R., Soulieres, D., Tahara, M., Castro Junior, G. de C., et al. (2019). Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet, 394( 10212), 1915-1928. doi:10.1016/S0140-6736(19)32591-7
NLM
Burtness B, Harrington KJ, Greil R, Soulieres D, Tahara M, Castro Junior G de C, Psyrri A, Baste N, Neupane P, Bratland A. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study [Internet]. Lancet. 2019 ; 394( 10212): 1915-1928.[citado 2024 ago. 31 ] Available from: https://doi.org/10.1016/S0140-6736(19)32591-7
Vancouver
Burtness B, Harrington KJ, Greil R, Soulieres D, Tahara M, Castro Junior G de C, Psyrri A, Baste N, Neupane P, Bratland A. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study [Internet]. Lancet. 2019 ; 394( 10212): 1915-1928.[citado 2024 ago. 31 ] Available from: https://doi.org/10.1016/S0140-6736(19)32591-7
Artigo de periodico
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial (2019)
Mok, Tony S. K; Wu, Yi-Long; Kudaba, Iveta; Kowalski, Dariusz M; Cho, Byoung Chul; Turna, Hande Z; Castro Junior, Gilberto de; Srimuninnimit, Vichien; Laktionov, Konstantin K; Bondarenko, Igor
Fonte: Lancet. Unidade: FM
Assuntos: NEOPLASIAS PULMONARES, IMUNOHISTOQUÍMICA, QUIMIOTERAPIA, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MOK, Tony S. K et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet, v. 393, n. 10183, p. 1819-1830, 2019Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(18)32409-7. Acesso em: 31 ago. 2024.
APA
Mok, T. S. K., Wu, Y. -L., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., et al. (2019). Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet, 393( 10183), 1819-1830. doi:10.1016/S0140-6736(18)32409-7
NLM
Mok TSK, Wu Y-L, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro Junior G de, Srimuninnimit V, Laktionov KK, Bondarenko I. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial [Internet]. Lancet. 2019 ; 393( 10183): 1819-1830.[citado 2024 ago. 31 ] Available from: https://doi.org/10.1016/S0140-6736(18)32409-7
Vancouver
Mok TSK, Wu Y-L, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro Junior G de, Srimuninnimit V, Laktionov KK, Bondarenko I. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial [Internet]. Lancet. 2019 ; 393( 10183): 1819-1830.[citado 2024 ago. 31 ] Available from: https://doi.org/10.1016/S0140-6736(18)32409-7
Artigo de periodico
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial (2019)
Heerspink, Hiddo J. L; Parving, Hans-Henrik; Andress, Dennis L; Bakris, George; Correa-Rotter, Ricardo; Hou, Fan-Fan; Kitzman, Dalane W; Kohan, Donald; Makino, Hirofumi; Burdmann, Emmanuel de Almeida
Fonte: Lancet. Unidade: FM
Assuntos: ENVELHECIMENTO, IDOSOS, DIABETES MELLITUS, NEFROPATIAS, MÉTODO DUPLO-CEGO, RESULTADO DE TRATAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HEERSPINK, Hiddo J. L et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet, v. 393, n. 10184, p. 1937-1947, 2019Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(19)30772-X. Acesso em: 31 ago. 2024.
APA
Heerspink, H. J. L., Parving, H. -H., Andress, D. L., Bakris, G., Correa-Rotter, R., Hou, F. -F., et al. (2019). Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet, 393( 10184), 1937-1947. doi:10.1016/S0140-6736(19)30772-X
NLM
Heerspink HJL, Parving H-H, Andress DL, Bakris G, Correa-Rotter R, Hou F-F, Kitzman DW, Kohan D, Makino H, Burdmann E de A. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial [Internet]. Lancet. 2019 ; 393( 10184): 1937-1947.[citado 2024 ago. 31 ] Available from: https://doi.org/10.1016/S0140-6736(19)30772-X
Vancouver
Heerspink HJL, Parving H-H, Andress DL, Bakris G, Correa-Rotter R, Hou F-F, Kitzman DW, Kohan D, Makino H, Burdmann E de A. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial [Internet]. Lancet. 2019 ; 393( 10184): 1937-1947.[citado 2024 ago. 31 ] Available from: https://doi.org/10.1016/S0140-6736(19)30772-X

Unidades USP

ReP

Filtros

Autores

Autores USP

Assuntos

Agência de fomento

Afiliação dos autores externos normalizada

Afiliação dos autores externos não normalizada

País das instituições de afiliação dos autores externos